Please use this identifier to cite or link to this item:
Title: Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo
Authors: Sariya Mapoung
Shugo Suzuki
Satoshi Fuji
Aya Naiki-Ito
Hiroyuki Kato
Supachai Yodkeeree
Natee Sakorn
Chitchamai Ovatlarnporn
Satoru Takahashi
Pornngarm Limtrakul
Pornngarm Limtrakul
Keywords: Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jun-2020
Abstract: © 2020 MDPI AG. All rights reserved. Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability.
ISSN: 14203049
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.